Turing Pharmaceuticals, the drug company that jacked up the price of a drug used by AIDS and cancer patients by more than 5,000%, is facing an antitrust probe by New York Attorney General Eric Schneiderman.
The drug company raised the price of Daraprim, a 62-year old drug no longer under patent protection, to $750 a tablet from $13.50.
The drug’s main use is to treat life-threatening parasitic infections but it is also needed by some infants and patients with AIDS. The price hike sparked howls of protest and the company promised to lower the price but has yet to do so.
The investigation, which was confirmed by Schneiderman’s office, is looking at whether Turing is restricting the distribution of Daraprim to thwart generic competition that would prevent it from maintaining the massive price increase. The office is concerned Turing restricted distribution of the drug specifically so generic drug manufacturers couldn’t get the samples they need to create their own version.
Full content: Human Rights Campaign
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Turkish Antitrust Authority Approves Tofaş Takeover of Stellantis Distribution Unit
Apr 20, 2025 by
CPI
Ohio Sues United Wholesale Mortgage Over Alleged Broker Collusion
Apr 20, 2025 by
CPI
Italy Reconsiders Digital Services Tax as US Tech Pressure Mounts
Apr 20, 2025 by
CPI
Japan’s Antitrust Regulator to Warn Top Tokyo Hotels Over Pricing Information Sharing
Apr 20, 2025 by
CPI
Senate Judiciary Committee Advances Bipartisan Bills to Address Drug Pricing and Competition
Apr 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Airline Industry
Apr 10, 2025 by
CPI
Boosting Competition in International Aviation
Apr 10, 2025 by
Jeffrey N. Shane
Reshaping Competition Policy for the U.S. Airline Industry
Apr 10, 2025 by
Diana L. Moss
Algorithmic Collusion in the Skies: The Role of AI in Shaping Airline Competition
Apr 10, 2025 by
Qi Ge, Myongjin Kim & Nicholas Rupp
Competition in U.S. Airline Markets: Major Developments and Economic Insights
Apr 10, 2025 by
Germán Bet